CAS: 1187-84-4; S-Methyl-L-Cysteine

相似化合物

7728-98-5 66255-16-1 138021-87-1

上下游产品

CAS号34017-27-1 S-甲基-l-半胱氨酸甲酯盐酸盐 | CAS号52-90-4 L-半胱氨酸 | CAS号74-88-4 碘甲烷 | CAS号16637-59-5 N-乙酰基-S-甲基-L-半胱氨酸 | CAS号52-89-1 L-半胱氨酸盐酸盐(无水物) | CAS号616-38-6 碳酸二甲酯 | CAS号18412-81-2 十二烷基二甲基碘化锍 | CAS号64969-77-3 hexadecyl-dimet... | CAS号50-89-5 beta-胸苷 | CAS号108-95-2 苯酚 | CAS号19651-44-6 S-methyl-DL-cysteine | CAS号74-93-1 甲硫醇 | CAS号75-18-3 二甲基硫 | CAS号56-41-7 L-丙氨酸 | CAS号56-45-1 L-丝氨酸 | CAS号56-84-8 L-天门冬氨酸 | CAS号52-90-4 L-半胱氨酸 | CAS号6853-87-8 S-甲基-L-半胱氨酸亚砜 | CAS号3226-62-8 L-Alanine, 3-[(... | CAS号100-61-8 N-甲基苯胺

📜N-乙酰基-S-甲基-L-半胱氨酸置于n-Acetylornithine Deacetylase From Escherichia Coli,Cobalt(II) Chloride体系中,用 Aq. Phosphate Buffer 用作溶剂,化学反应 24.0H,反应生成S-甲基-L-半胱氨酸
参考文献:通过 1H NMR 直接监测氨基酸底物的生物催化脱乙酰作用揭示了底物特异性的细节
标题:通过 1H NMR 直接监测氨基酸底物的生物催化脱乙酰作用揭示了底物特异性的细节
摘要:氨基酸是关键的合成构件,可以通过生物催化方法制备对映体纯形式.我们发现l-选择性鸟氨酸脱乙酰酶 Arge 催化多种n-酰基氨基酸底物的水解.该活性通过1 H NMR 光谱来揭示,该光谱监测了乙酸盐产物的清晰信号的出现.此外,该测定还使用可以采用不同旋转异构体构象的底物来探测生物催化剂的微妙结构选择性.
Doi:10.1039/d1Ob00122A

专利信息

专利号:WO-2023039068-A1
优先权日:2021-09-08
标题:Compositions and methods for synthesis of peptide nucleic acid intermediates
发明人：COULL JAMES M; GILDEA BRIAN D
权利人:NEUBASE THERAPEUTICS INC
摘要:The present disclosure provides intermediates for the synthesis of peptide nucleic acid (PNA) backbones and monomers, such as cyclic intermediates, and methods of making the same.

专利号:US-7459443-B2
优先权日:1999-04-08
标 题 :Synthesis of biologically active compounds in cells
发明人：SERGEEV PAVEL
权利人:SERGEEV PAVEL
摘要:This invention relates to a new method of synthesis of biologically active substances of determined structure directly in the cells of living organisms containing specific RNA or DNA molecules of determined sequence. The method is based on the hybridization of two or more oligomers bound with biologically inactive precursors of biologically active substances to specific RNA or DNA in vivo in the cells of living organisms. After hybridization of the oligomers to RNA or DNA the biologically inactive precursors bound to the 5′ and/or 3′ ends of the oligomers can interact with each other to make biologically active form of the substances. This changing of properties is due to chemical reactions which bind the biologically inactive precursors through a chemical bond into a biologically active form of the whole compound.

专利号:US-2007088086-A1
优先权日:1999-08-16
标题 :Method of using synthetic L-Se-methylselenocysteine as a nutriceutical and a method of its synthesis
发明人：SPALLHOLZ JULIAN E; REID TED W; WALKUP ROBERT D
权利人:PHARMASE INC
摘要:A synthesis of and use for L-Se-methylselenocysteine as a nutriceutical is described, based upon the knowledge that L-Se-methylselenocysteine is less toxic than L-selenomethionine towards normal cells. The synthesis proceeds by mixing N-(tert-butoxycarbonyl)-L-serine with a dialkyl diazodicarboxylate and at least one of a trialkylphosphine, triarylphosphine, and phosphite to form a first mixture that includes N-(tert-butoxycarbonyl)-L-serine β-lactone. Methyl selenol or its salt is mixed with the N-(tert-butoxycarbonyl)-L-serine β-lactone to form a second mixture that includes N-(tert-butoxycarbonyl)-Se-methylselenocysteine. The tert-butoxycarbonyl group is removed from the N-(tert-butoxycarbonyl)-Se-methylselenocysteine to form L-Se-methylselenocysteine. This synthesis significantly improves the manufacturability, manufacturing efficiency, and utility of this naturally occurring rare form of organic-selenium. L-Se-methylselenocysteine formed, for example, in this manner may be used as a nutriceutical for supplementation into the diets of humans or animals for various beneficial purposes, such as, for example, to prevent or reduce the risk of developing cancer.

专利号:EP-1205471-A1
优先权日:2000-10-02
标题:A method of using synthetic L-SE-Methylselenocysteine as a nutriceutical and a method of its synthesis
发明人：SPALLHOLZ JULIAN E; REID TED W; WALKUP ROBERT D
权利人:PHARMASE INC
摘要:A synthesis of and use of L-Se-methylselenocysteine as a nutriceutical isndescribed, based upon the knowledge that L-Se-methylselenocysteine is lessntoxic than L-selenomethionine towards normal cells. The synthesis proceedsnby mixing N-(tert-butoxycarbonyl)-L-serine with a dialkyl diazodicarboxylatenand at least one of a trialkylphosphine, triarylphosphine and phosphite to formna first mixture that includes N-(tert-butoxycarbonyl)-L-serine β-lactone.nMethyl selenol or its salt is mixed with the N-(tert-butoxycarbonyl)-L-serine β-lactonento form a second mixture that includes N-(tert-butoxycarbonyl)-Se-methylselenocysteine.nThe text butoxycarbonyl group is removed from the N-(tert-butoxycarbonyl)-Se-methylselenocysteinento form L-Se-methylselenocysteine.nThis synthesis significantly improves thenmanufacturability, manufacturing efficiency and utility of this naturallynoccurring rare form of organic-selenium. L-Se-methylselenocysteine formed,nfor example, in this manner may be used as a nutriceutical for supplementationninto the diets of humans or animals for various beneficial purposes, such as, fornexample, to prevent or reduce the risk of developing cancer.

专利号:US-2020354404-A1
优先权日:2019-05-09
标 题 :Peptidomimetic agents, synthesis and uses thereof
发明人：AL-ABED YOUSEF
权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
摘要:Compounds for use in synthesis of peptidomimetic agents; synthesis of peptidomimetic agents; peptidomimetic diagnostic and therapeutic agents; and uses of the compounds and peptidomimetic agents in drug discovery, diagnosis, prevention and treatment of diseases are described.

专利号:US-2013243770-A1
优先权日:2005-10-14
标 题:Treating diabetes using inhibitors of il-1
发明人：LAU JESPER
权利人:NOVO NORDISK AS
摘要:The present invention describes a method of treating diabetes or metabolic syndrome with a compound that inhibits (a) IL-1, (b) the synthesis of IL-1, or (c) the release of IL-1.